growth hormone
Drug36 months
NCT Number: NCT01897753
The purpose of this protocol is to retrospectively study the influence of age at start of growth hormone (GH) treatment on height gain in children born small for gestational age (SGA).
Looking for future studies?
Notify Me4 year and older
All sexes
Observational
H. Germans Trias i Pujol, Badalona, Barcelona, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
36 months
Time frame: 36 months
height SDS of SGA children after 36 months of treatment
Time frame: 36 months
Time frame: 36 months
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.
Pfizer
Industry
Retrospective Study Of The Influence Of Age At Start Of Growth Hormone (Gh) Treatment On Height Gain In Children Born Small for Gestational Age (SGA)
Acronym: GH-RAST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01897766
Small For Gestational Age (SGA)
View Trial DetailsNCT00333333
Blood Platelet Disorders, Cytopenia
Newark, Delaware, United States
View Trial DetailsNCT07559773
Asthma Childhood, Atopic Dermatitis
View Trial DetailsNCT06723392
Bacteriuria, Bacteriuria (Asymptomatic) in Pregnancy
Dhaka, Bangladesh
View Trial Details